Summit Therapeutics (SMMT) Tops Q1 EPS by 2c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q1 EPS of (GBP0.07), GBP0.02 better than the analyst estimate of (GBP0.09).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
- Needham Upgrades Silicom Ltd. (SILC) to Buy
- Barclays Downgrades Dana Holding (DAN) to Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
